

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

P. 11

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C08H 1/00, C08J 3/075, G02B 1/04,</b> <b>A61L 15/32</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/15352</b> <b>(43) International Publication Date:</b> 8 June 1995 (08.06.95)
<b>(21) International Application Number:</b> PCT/CA94/00650 <b>(22) International Filing Date:</b> 24 November 1994 (24.11.94) <b>(30) Priority Data:</b> 08/159,559 1 December 1993 (01.12.93) US <b>(71) Applicant:</b> UNIVERSITE DU QUEBEC A MONTREAL [CA/CA]; Pavillon Athanase-David, local D-3502, 1430 rue Saint-Denis, Montreal, Quebec H2X 3J8 (CA). <b>(72) Inventor:</b> FORTIER, Guy; 2153 rue Marcil, Montreal, Quebec H4A 2Z2 (CA). <b>(74) Agent:</b> LECLERC, Alain, M.; Goudreau Gage Dubuc & Martineau Walker, 3400 The Stock Exchange Tower, P.O. Box 242, Place Victoria, Montreal, Quebec H4Z 1E9 (CA).		<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ALBUMIN BASED HYDROGEL		
<b>(57) Abstract</b> <p>Novel bioartificial hydrogels consisting of a three-dimensional crosslinked mixture of: (a) a bifunctionalized polyethylene oxide, activated with an activating agent, dissolved in an aqueous solution; and (b) albumin type protein. The novel hydrogels are based on the crosslinking of albumin type protein of various sources including, for example, bovine serum albumin, lactalbumin or ovalbumin, with a bifunctionalized polyethylene oxide, most preferably polyethylene glycol, or a mixture of bifunctionalized polyethylene oxides preferably polyethylene glycol, of various molecular masses (Mr 2,000 to 35,000), dissolved in aqueous solution in adequate proportions. Also provided is a method and conditions for preparing the novel hydrogels. Also divulged are a variety of biomedical applications for the novel hydrogels. Additionally, it has been found that the mechanical properties of the novel hydrogels can be improved by adding to the casting solution unreactive polyethylen glycol or other inert polymer of high molecular masses (Mr &gt; 100,000). In general terms the novel hydrogels possess advantageous properties such as shape retention and shape memory, high water content (more than 94 % (w/w) based on the dry weight of the hydrogel), good mechanical and optical properties. The hydrogels exhibit additional characteristics which may render them extremely useful in the pharmaceutical and medical areas due to other advantageous properties such as biocompatibility, resistance to proteases action, slow release of various drugs, hydrophilic surface, good oxygen permeability, controlled porosity.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

## ALBUMIN BASED HYDROGEL

## FIELD OF THE INVENTION

This invention relates to the preparation of high water content bioartificial hydrogels obtained from the crosslinking of albumin type proteins, such as bovine serum albumin (hereinafter referred to as BSA) with bifunctionalized polyethylene glycol, or other suitable bifunctionalized polyethylene oxide, of various molecular masses, in different proportions, in an aqueous solution.

## BACKGROUND OF THE INVENTION

The term "hydrogel" refers to a class of polymeric materials which are extensively swollen in a aqueous medium, but which do not dissolve in water. In general terms, hydrogels are prepared by polymerization of a hydrophillic monomer under conditions where the polymer becomes crosslinked in a three dimensional matrix sufficient to gel the solution. Bioartificial or semi-synthetic hydrogels may also be prepared by the covalent addition of the hydrophillic polymer to the surface of a protein so that the polymer and protein form a further covalently crosslinked three dimensional matrix. This class of hydrogels made from a synthetic polymer and a biopolymer has been recently reviewed and it has been proposed to name this new class of biomaterials as bioartificial polymeric material or hydrogel (Giusti, P et al, Trends in Polymeric Science, (:261-267, 1993).

The usefulness and multiplicity of desirable applications of hydrogels in medicine and other areas as well as their composition and methods of their preparation have been well documented. For example, in a two volume book series, Hydrogels in medicine and pharmacy, vol. 1 & 2, N. A. Peppas ed. CRC Press publ., USA, 1986; or other books such as Polymer in Medicine, R.M. Ottenbrite and E. Chiellini, Technomic publ., USA, 1992, as well as several scientific publications such as:

- 2 -

5     The design of hydrogel for biomedical applications, by P.H. Corkhill, C.J. Hamilton and B.J. Tighe in *Crit. Rev. Biocompatibility*, 5:363-435, 1990; Bioartificial Polymeric Materials: a new method to design biomaterials by using both biological and synthetic polymers, P.Giustic, L.Lasseri and L. Lelli, Trends in Polymeric Science, 9:261-267, 1993.

10     Some of the more notable biomedical applications of hydrogels include contact lenses, non-toxic in-vivo controlled drug release implants, wound dressings, cell growth matrices. Novel or improved hydrogels having improved properties, applications or ease of preparation are of course required.

15     The present invention concerns a novel bioartificial hydrogel prepared from the crosslinking of a polyethylene oxide, or derivative thereof, preferably polyethylene glycol (hereinafter arbitrarily referred to in its abbreviated form as PEG), with albumin type protein.

20     With the benefit of the above described background of hydrogels, the known prior art will now be addressed.

#### PRIOR ART

25     With regards to bioartificial hydrogels, methods for the covalent addition of hydrophillic polymers such as monomethoxy-polyethylene glycol (hereinafter referred to as mPEG) to the surface of a protein have been successfully developed using a variety of reagents (review in *Biotechnol. Appl. Biochem.* 17:115, 30     1993; *TIBTECH*, 4:190, 1986 & 6:131, 1988). mPEG has generated a great deal of interest when it was first used to modify the surface of proteins and enzymes in the aim of reducing their immunogenicity and to increase their blood clearance time for potential *in vivo* applications (J. Biol. Chem, 252:3578, 1977 and 252:3582, 1977). Such 35     soluble modified proteins or enzymes have shown an

- 3 -

increase in their structural resistance against proteolytic action of proteases (*J. Ferment. Bioeng.*, 71:137-139, 1991), an increase of their rate of adsorption by the gastro-intestinal tractus (*Biol. Chem. Hoppe Seyler* 101:3715, 1990) and an increase of their cellular influx (*Proc. Natl. Acad. Sci. USA*, 84:1487, 1987). Such modified enzymes have also shown a good activity as microparticulate suspensions in organic solvents (*Enzyme Microb. Technol.*, 14:96-100, 1992; *TIBECH*, 4:190, 1986 & 6:131, 1988). mPEG can even be used as a blood substitute when covalently bound to the protein hemoglobin (*J. Prot. Chem.* 10:61-67, 1991). When the surface of a material is covered by mPEG, the protein adsorption on this surface is reduced (2nd Congress on Biomaterials, USA 1984) as well as the complement activation and the platelet adhesion (*Biomaterials*, 13:113-118, 1992).

Recently, the preparation of a gel using a mixture of copolymerized acrylic derivatives of chymotrypsin and polyethylene oxide acrylate derivatives has been described in the literature (*Int. J. Peptide Protein Res.* 38:273-277, 1991). The gel was utilized successfully in organic solvents for peptide synthesis. However, the authors do not offer any mention regarding the characterization of the protein aggregates obtained using this procedure. The protaneous gel cannot be considered as an hydrogel since the reactions were performed in an organic medium as opposed to an aqueous medium.

A detailed review on the chemistry of polyethylene glycol and its biotechnological and biomedical applications is found in (Polyethylene glycol chemistry, Biotechnological and biomedical applications, Milton Harris ed. Plenum Press, 1992) as well as the book entitled Hydrogels in medicine and pharmacy, ed. by N.A. Peppas, especially the chapter 4 of Volume 2 which focuses on poly(ethylene oxide) and related hydrogels.

- 4 -

Many PEG based hydrogels are therein described without any mention of crosslinking of PEG with a protein. It is demonstrated that PEG can be considered as an useful polymer and hydrogel by itself for many biomedical uses because of its specific and advantageous properties: it is a non thrombogenic material, it presents a low toxicity, it is approved by FDA (Food & Drug Agency) as polymer in foodstuffs and pharmaceutical products used via injection, topical or oral routes. When PEG was converted into a crosslinked network (an hydrogel), it passed regulatory requirements. One of the most popular polymer for hydrogel synthesis was for some time the polyHEMA which unfortunately suffered biocompatibility problems which ultimately restricted its usage.

Presently the majority of hydrogels are prepared from a mixture of polymer or block copolymer crosslinked by radiation or chemical reagent or simply prepared by polymerization and reticulation of a monomeric solution. One important drawback arising from these methods are the inherent difficulties in achieving reproducibility in specific porosity and degree of crosslinking which ultimately affect many characteristics of the resulting hydrogel. Control of the chain length of the polymer used, the hydrophilicity, and the molecular masses of the copolymer (cross linker) along with controlled mild aqueous reaction conditions, are the key to success in achieving reproducibility, size pore control, water swelling control, and geometry control of the hydrogel.

U.S. Pat No. 4,101,380, the specification of which is incorporated herein by reference, discloses a very wide variety of reagents useful to activate polyethylene oxide in the aim of obtaining a bifunctionalized polyethylene oxide or polyalkene oxide. When those reagents are used to crosslink PEG with a gelatin preformed membrane, a crosslinked gelatin-PEG membrane was obtained and was characterized by an high

- 5 -

liquid swelling capacity. However, other embodiments described in the patent provided very low yield of protein crosslinking (in the order of of about 2%). In said patent, there is no mention or suggest that advantageous hydrogels could be obtained by cross-linking of an albumin or an other native protein in an aqueous solution with activated polyethylene oxide. Moreover, said patent states that the use of a carbonate derivative of polyethylene oxide is not recommended and not useful should attempts be made to obtain crosslinking of the polymer with a protein or enzyme. This is explained as being due to the high pH required for the subsequent crosslinking reaction which could induce denaturation of enzymes or proteins.

The present invention demonstrates in sharp contrast that the use of a carbonate polyethylene oxide derivative should be very useful for the preparation of cast hydrogels having reproducible specific geometries as required, for example, when making contact lenses or devices for controlled drug release. Although the pH of reaction is higher than 9 during cross-linking with a protein or enzyme, the present invention confirms that PEG carbonate derivatives are useful reagents for enzyme or protein modifications which prevent denaturation of many enzymes (catalase, peroxidase, superoxide dismutase, acid phosphatase, glucose oxidase, lysozyme, and asparaginase).

U.S. Pat No. 4,161,948 discloses synthetic membranes (artificial skin) for wound dressings. Said patent suggests that when preparing the membranes, it is preferable that the  $\delta$ -amino acid polymers employed be crosslinked with a diol such as polyoxyethylene glycol, in order to achieve properties resembling those of natural human collagen. Polypeptides as a source of polyamino functional groups were not mentioned in said patent. According to said patent,  $\delta$ -amino acid polymers are prepared by a polymerisation process which results in

- 6 -

a statistically distributed polymer in a wide range of molecular weights. The fabrication of the artificial skin described in said patent is obtained via a complex multi step process. It is obvious, from the disclosure of said patent, that the inventors, are experiencing great difficulty in controlling the porosity and the cross-linking of the synthetic membrane and are resorting to a complex method.

U.S. Pat No. 4,752,627 discloses a contact lens which contains polymerized ethylene glycol moieties as side chains to the major polymer (HEMA, polyvinyl pyrrolidone) components. Said patent explains that the use of PEG as a side chain component contributes to the ability of the lens to resist to the absorption of proteins present in human tears. Depending on the amount of the hydrophobic cross-linker used to prepare the hydrogel, an equilibrium water content varying from 18 to 60% was obtained. Such a degree of water swelling is unfortunately not sufficient to allow free diffusion of oxygen similar to the corresponding rate in a solution.

U.S. Pat. No. 4,814,182 discloses the preparation of a controlled release device based on a hydrogel coated with an impermeable layer on at least one side of the device. The hydrogel was obtained from the polymerization of block copolymers comprising both hydrophillic and hydrophobic domains, preferably polyethylene oxide methacrylate which reacted with a substituted or unsubstituted cyclic mono or polyether having from 3 to 6 ring atoms or cyclic imine. The use of a protein as a polyamino groups source is not mentioned in said patent.

U.S. Pat. No. Reissue 33,997 discloses a contact lens based on the crosslinking of collagen with an ethylenically unsaturated compound of varying length from one to six carbons. The hydrogel described therein displayed good biological stability to protease digestion and protein fouling (adsorption).

SUBSTITUTE SHEET



- 7 -

**SUMMARY OF THE INVENTION**

Unexpectedly, a family of novel hydrogels has been discovered. The novel hydrogels are polymerized hydrophillic water-swellaable gels essentially consisting of a crosslinked mixture of: (a) a bifunctionalized polyethylene oxide, activated with a suitable activating agent, dissolved in an aqueous solution; and (b) albumin type protein albumin. The novel hydrogels are based on the crosslinking of a protein, namely albumin of various sources including, for example, BSA, with a bifunctionalized polyalkene oxide preferentially polyethylene oxide, and most preferably polyethylene glycol, or a mixture of bifunctionalized polyalkene oxides of various molecular masses (Mr 2,000 to 35,000) dissolved in aqueous solution, in adequate proportions.

The present invention also provides a method and conditions for preparing the novel hydrogels.

A variety of biomedical applications for the novel hydrogels are also envisaged and method for preparing the products related to those applications are claimed. Additionally, it has been found that the mechanical properties of the novel hydrogels can be improved by adding to the casting solution unreactive PEG or other inert polymers of high molecular masses (Mr > 100,000).

Accordingly, the novel hydrogels possess many advantageous properties such as shape retention and shape memory, they can reach very high water content (more than 94% (w/w) based on the dry weight of the hydrogel). The novel hydrogels also possess good mechanical and optical properties. The hydrogels further possess more characteristics which may render them extremely useful in the pharmaceutic and medical areas due to their advantageous properties such as biocompatibility, resistance to proteases action, slow release of various

- 8 -

drugs, hydrophillic surface, good oxygen permeability, controlled porosity, and other desirable properties.

These and other objectives can be achieved by practising the teachings disclosed herein. It is to be noted that specific examples relating to the possible applications of the novel hydrogels will be described and do not represent an exhaustive enumeration and consequently do not limit all other possible applications of the novel hydrogels which are to be contemplated and understood.

#### BRIEF DESCRIPTION OF THE DRAWINGS

These and other advantages of this invention will be readily apparent when considered in light of the following description when considered in light of the drawing set forth with comprises the following figures:

FIG. 1 is a graphical representation of the effect of the molecular masses of PEG (horizontal scale) on the gelling time (vertical scale) of a BSA-PEG hydrogel in two different buffer pH solutions (the filled dots indicate a 0.1M borate buffer of pH 9.4 and the open dots indicate a 0.1M borate buffer of pH 8.8).

FIG. 2 is a graphical representation of the effect of the PEG/NH<sub>2</sub> ratio (vertical scale) on gel formation with regards to PEG molecular mass (horizontal scale) with dark bars representing maximal values and light bars representing minimal values.

FIG. 3 is a graphical representation of absorbance (vertical scale) versus wavelength (horizontal scale) for hydrogels obtained with PEG, Mr 10,000, crosslinked with different sources of albumins. For UV spectra analysis, the hydrogels were swollen in PBS buffer containing sodium azide 0.02 %.

FIG. 4 shows the fractional release (vertical scale) of three example drugs over time (horizontal scale).

- 9 -

FIG. 5 shows the fractional release (vertical scale) of theophylline as an example drug over time (horizontal scale) for hydrogels of the present invention prepared with BSA and PEG of various molecular masses.

5           FIG. 6 shows the operational stability, expressed in percentage of residual activity (vertical scale) over time (horizontal scale) for acid phosphatase immobilized in BSA-PEG, Mr 10,000, in the presence of 10 mM of p-nitrophenylphosphate (flow rate of 1,25 ml/min).


## 10           DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention relates to novel hydrogels, their preparation, and applications. The novel hydrogels can, for example and without necessary or implied limitations, be used for making contact lenses, controlled drug  
15           release devices, immobilisation matrix for enzymes or cells of therapeutic interest as enzyme correction, wound dressing and artificial skin.

In a preferred embodiment, the hydrogels generally contain a significant amount of polyethylene glycol crosslinked with a protein, namely albumin from  
20           various sources such as bovine serum (BSA), (M.W., 67,000), egg (M.W., 43,000) or milk (M.W., 14,400). The polyethylene glycol is activated to form water soluble polyethylene oxide derivatives of the general formula 1

25

:



wherein X can be any type of functionalized groups able to react with an amino, a S-H, an OH or a COOH group brought by a protein,

30           and n can vary from 45 to 800 which corresponds to commercial PEG of Mr ranging from 2,000 to 35,000.

The activation of polyethylene glycol by a reagent such as 4-nitrophenyl chloroformate is known to be possible by various methods described in patents and  
35           other scientific literature (U.S. Pat. No. 4,101,380,

- 10 -

Biotech. Appl. Biochem, 17:115, 1993; Polyethylene glycol Chemistry: Biotechnical and Biomedical applications, ed J. M. Harris, chap 21, pp. 347-370, Plenum Press, N.Y. 1992), which are incorporated herein  
5 by reference.

## EXPERIMENTAL

### Activation of PEG

In accordance with a preferred embodiment, the activation of PEG to obtain a reagent able to react with  
10 amino groups will now be briefly described.

Polyethylene glycol of various molecular masses (n varying from 45 to 800) were activated using 4-nitrophenyl chloroformate in order to obtain a series of PEG dinitrophenyl carbonates (Biotech. Appl. Biochem,  
15 17:115, 1993). The method will now be narrated in more detail. Before use, all PEGs had been dehydrated by dissolving 1.0 mmole of a PEG in acetonitrile and refluxing at 80°C for 4 hours in a Soxhlet (trade-mark) extractor containing 2.0 g of anhydrous sodium sulfate.  
20 The dehydrated solution containing 1.0 mmole of PEG was activated in the presence of at least 3.0 mmoles of 4-nitrophenyl chloroformate in acetonitrile containing up to 5 mmoles of triethylamine. The reaction mixture was heated at 60°C for 5 hours. The reaction mixture was cooled and filtered and the synthesized PEG-dinitrophenyl carbonate was precipitated by the addition of ethyl ether at 4°C. The percentage of activation was evaluated by following the release of p-nitrophenol from the activated PEG in 0.1 M borate buffer solution, pH 8.5, at 25°C.  
25 The hydrolysis reaction was monitored at 400 nm until a constant absorbance was obtained. The purity was calculated based on the ratio of the amount of p-

30

- 11 -

nitrophenol released and detected spectrophotometrically versus the amount of p-nitrophenol expected to be released per weight of activated PEG used for the experiment. The purity of the final products was found to be around 90%.

#### Preparation of the hydrogel of albumin crosslinked with PEG.

Covalent cross-linking of the activated PEG to albumin of various sources, for example serum (BSA), milk (lactalbumin) or egg (ovalbumin), was obtained by adding to one ml of 5% (w/v) protein solution (in either phosphate or borate buffer) different amounts of the activated PEG (from 7 to 13% w/v), followed by vigorous mixing until all the PEG powder was dissolved. The crosslinking reaction was performed at pH 8.8 except for PEG molecular masses inferior to 5000 for which a more basic buffer (pH 9.3) was used. The ratio of reagents (PEG/NH<sub>2</sub> free groups of protein) was determined taking into account that bovine serum albumin (BSA) has 27 accessible free NH<sub>2</sub> groups. The hydrogel obtained was incubated in 50 mM borate buffer pH 9.8 in order to hydrolyse the unreacted PEG-dinitrophenyl carbonate. The released p-nitrophenol, the unlinked PEG, and the free BSA were eliminated from the gel matrix by washing the hydrogel in distilled water containing NaN<sub>3</sub> 0,02% for many hours.

In these experimental conditions, the rate of polymerization was found to be a function of the pH of the reaction. When the reaction was performed at pH 7.8, the time required for gel formation is 1000 min contrary to what was observed at pH 10.3 where the gelification is obtained in less than 5 minutes.

Referring now to Figure 1, it is shown that at an intermediary pH of reaction values, intermediary reaction times were obtained.

- 12 -

Referring now to Figure 2, the PEG/NH<sub>2</sub> ratio (defined as the molar ratio of PEG activated groups versus albumin accessible NH<sub>2</sub> group) leading to the formation of a solid hydrogel ranged from 0.12 to 10 depending of the molecular masses of PEG used. The optimum ratio was found to corresponds to the ratio where the release of albumin and PEG are at a minimum during the washing steps. In general terms, the higher the Mr of PEG used, the smaller is the average ratio PEG/NH<sub>2</sub> needed to obtain a solid hydrogel, see Figure 2. The decrease of the ratio is thought to be partially explained by an increase of steric hindrance when high molecular masses of PEG are used.

#### Evaluation of the degree of swelling of the hydrogel.

After completion of washing (until a colourless gel is obtained, which corresponds in this case to the elimination of any residual trace of p-nitrophenol), the hydrogels were dehydrated under vacuum or by acetone washes. In order to evaluate the effects of pH and of the ionic strength on the water uptake of the hydrogel, the dry PEG-albumin gels were weighed and incubated in various buffer solutions (acetate, phosphate or borate buffers) at various levels of pH and molarities. The swelling of the dry hydrogel was periodically evaluated by measuring the increase of gel volume in a graduated cylinder or by weighing. The swelling solution was changed once during the procedure. The swelling factor (SF) is calculated from equation 2 which is adapted from the work on the polyvinyl alcohol hydrogels (Urushisaki et al. , *Int J. Pharm.*, 58:135, 1990):

$$\text{swelling factor} = (W_s - W_{th})/W_{th} \quad (2)$$

were  $W_s$  is the final weight after swelling and  $W_{th}$  is the dry weight measured at the end of experiment by drying the hydrogel at 70°C until complete

- 13 -

dehydration. The swelling capacity of an hydrogel can also be described by an equilibrium water content value (EWC) which is defined in equation 3:

$$\text{EWC} = (\text{weight of water/weight of the swollen hydrogel}) \times 100 \quad (3)$$

The swelling kinetics in a PBS solution at pH 7.3 at 20°C, were evaluated for hydrogels prepared using PEG of Mr of 10,000 (PEG/NH<sub>2</sub> molar ratio of 1.3) and PEG of Mr of 20,000 (PEG/NH<sub>2</sub> molar ratio of 0.5). For the hydrogels obtained with PEG 10,000 or PEG 20,000, a steady state in the swelling kinetic was observed after 100 and 80 hours, respectively. A linear velocity of the water uptake as a function of the square root of the time was observed during the first 8 hours for both hydrogels. For all the hydrogels (Mr from 3,350 to 20,000) the EWCs obtained in distilled water containing 0.02% of sodium azide showed a swelling EWC of 96.5 to 98%. In the absence of sodium azide, the EWC of every hydrogel became greater than 99%, a value at which the hydrogels obviously became fragile and their manipulation difficult.

Another series of swelling experiments was performed with different hydrogels made from various ratio of PEG/NH<sub>2</sub> in 50 mM borate buffer. The SF observed ranged from 14 to 21 with a maximum value observed for an hydrogel obtained with a PEG of Mr 10,000 (PEG/NH<sub>2</sub> molar ratio of 0.4). More details are provided in Table I below.

TABLE I

Evaluation of the swelling parameters (Swelling Factor and of the Equilibrium water content) of different hydrogels obtained using bovine serum albumin and various molecular masses of PEG, at the optimum (PEG/NH<sub>2</sub>) ratio.

Mr of PEG --	Ratio PEG-OH/NH <sub>2</sub>	Swelling Factor <sup>1</sup> X	Equilibrium water content <sup>1</sup> %
3,350	3.0	13.9	93.3
4,600	1.6	14.1	93.4
8,000	1.4	20.5	95.3
10,000	1.2	20.9	95.4
20,000	0.4	19.3	95.1

<sup>1</sup> These parameters were obtained by incubating the various hydrogels in 50 mM borate buffer pH 8.8 containing 0.02% sodium azide. In absence of azide and buffer, the equilibrium water content reached a value greater than 99%. At these values, all hydrogels are too fragile to be manipulated and broken easily.

#### Permeability of the hydrogel to oxygen

In a study on dissolved oxygen permeability for a range of hydrogels, Ng and Tighe found the log of permeability coefficient to be linearly related to the overall EWC (*Br. Polym. J.*, 8:78, 1976; 8:118, 1976). This relation was later confirmed by Refojo and Leong, (*J. Membran. Sci.*, 4:415, 1979). Using this relation along permeability data available in the literature, and considering an EWC at least greater than 94% at 20°C in an isotonic solution, the oxygen permeability of the hydrogels of the present invention is projected to approach the value of oxygen diffusion in a water solution (Corkhill et al, *Crit. Rev. Biocompatibility* 5:363, 1990).



- 15 -

**Translucidity of the various hydrogels.**

As shown in Figure 3, the absorption spectra of three different types of hydrogels of the present invention, obtained with PEG, Mr 10,000 and crosslinked to bovine serum albumin, lactalbumin or ovalbumin did not display any peak absorption for wavelengths greater than 340 nm (corresponding to the visible region of light spectrum). Due to their high transmittance in the visible region of the light spectrum, these hydrogels can be considered as a good material to elaborate contact lenses or ophthalmologic devices as well as wound covering devices (in this later case, the wound dressing transparency could allow the degree of healing to be visualized). The spectra given in figure 3 were obtained using an Hewlett-Packard diode array spectrophotometer for PEG Mr 10,000 hydrogels previously swollen in a phosphate buffer salts solution (PBS) containing sodium azide at 0.02% and placed directly in a custom made gel holder.

**Evaluation of the rheologic properties of the new family of hydrogels**

The rheologic properties of the hydrogels were evaluated using an Instron 4201 (trade-mark) instrument at room temperature. The viscoelasticity characteristics for hydrogels prepared with PEGs of Mr 3,350 and 20,000, respectively, swollen in 100 mM phosphate buffer, were established from their curves of gel deformation versus time at constant compression (0.5 cm/min) applied until the hydrogel collapsed. Up to 70% of compression, the hydrogel obtained using PEG of molecular mass of 20,000 and BSA exhibited a perfect or near perfect elastic behaviour and the gel breaking force was found to be 8 N/cm<sup>2</sup> (no correction of force was given to relate the increase of the contact surface with the increase of compression). With hydrogels obtained using PEG of Mr 3,350, the break of the gel appeared at 50% of

- 16 -

compression and required a force of 10.6 N/cm<sup>2</sup>. Based on these preliminary studies, a trend was observed between the increase of the molecular masses of PEG and the increase of the elasticity of the hydrogel.

5       **FURTHER DESCRIPTION OF APPLICATIONS AND POTENTIAL USES OF  
THE HYDROGELS OF THE PRESENT INVENTION**

Applications and potential uses of this new family of hydrogels in wet form include: 1) contact lens or other ophthalmic device; 2) slow drug released  
10       device such as capsule, cutaneous patch or implant; 3) matrix for immobilization of cells or enzymes for *in vivo*, *in vitro* or *ex vivo* use as a bioreactor or biosensor; 4) artificial skin; and 5) wound dressing.

A dry form of these hydrogels (obtained after  
15       dehydration under vacuum or in acetone) can also be used first as water or exudate absorbent in wound dressing, second as a slow or controlled drug release devices.

Some of these potential applications will now be discussed in the following examples which are to be  
20       construed as illustrative as opposed to limitative.

**EXPERIMENTAL**

**Slow or controlled drug release device.**

A thin film (3 mm thick) of hydrogel made from PEG of molecular masses of 10,000 and BSA, was cut into  
25       pastilles of 0.8 to 1.8 cm in diameter and used as a slow drug released devices. The pastille were loaded and allowed to swell overnight at room temperature in a solution containing the drug (250 µg/ml in phosphate buffer salts solution (PBS) in which 20%/vol of ethanol  
30       was added to dissolve the steroids). The pastilles were then fixed onto a microscope glass slab and its

- 17 -

circumference coated with white petroleum jelly in order to have only one releasing surface. The pastilles were incubated in PBS and the release of the drug from the pastilles was monitored in a closed circulatory device connected to a spectrophotometer. The drug release was monitored at the wavelength where the absorption of the drug was maximal, during more than ten hours. The release kinetics were analyzed to fit equation (4) (P.L. Ritger and N.A. Peppas, *J. Controlled release*, 8:37, 1987), which can be used to analyze the part of the curve corresponding to  $M_t/M_\infty < 0.60$  :

$$M_t/M_\infty = k t^n \quad (4)$$

where  $M_t$  and  $M_\infty$  are the amount of drug released at  $t$  and infinite time,  $k$  is a rate constant of the release and  $n$  is a value representing the mechanism of the release. For  $n = 0.5$ , the drug is released following a Fickian mechanism.

Referring now to **Figure 4**, the release patterns of three common drugs, namely theophylline, acetaminophen and hydrocortisone from hydrogels (active surface: 1.1 cm<sup>2</sup>, thickness 3 mm) prepared with BSA and PEG, Mr 10,000, are given. **Table 2** below provides the value of the exponent  $n$  along with the coefficient of correlation when equation 4 is used to fit the curves. The compounds studied are acetaminophen, cortisone, hydrocortisone, lysozyme, methylene blue, prednisone, tetracycline and theophylline.

TABLE 2

Compilation of the values of the exponent  $n$  (eq 4) along with the coefficient of correlation of the fit, and the diffusion coefficient (eq.5), assuming  $n = 0.5$ , for the compounds listed. Pastilles of BSA-PEG 10,000 (ratio was 1.1) were loaded in triplicate by immersion for 24 hours in solution containing 250  $\mu\text{g/ml}$  of the different compounds (see text). The release study was carried out in 30 ml of PBS at room temperature.

Drug	Exponent $n$	$r$	$D$ ( $\text{cm}^2/\text{s}$ )
Theophylline	0.511	0.999	$14.7 \cdot 10^{-7}$
Acetaminophen	0.596	0.998	$10.7 \cdot 10^{-7}$
Tetracycline	0.522	0.999	$10.1 \cdot 10^{-7}$
Cortisone	0.569	0.999	$8.6 \cdot 10^{-7}$
Hydrocortisone	0.562	0.999	$8.6 \cdot 10^{-7}$
Prednisone	0.557	0.999	$8.3 \cdot 10^{-7}$
Methylene blue	0.520	0.999	$8.3 \cdot 10^{-7}$
Lysozyme	0.520	0.999	$1.26 \cdot 10^{-7}$

For each compound shown in table 2, the value of the exponent  $n$  is very close to 0.5, which is indicative of a Fickian release process. The coefficient of diffusion,  $D$ , given in table 2 was calculated using equation (5) (R. Baker, *Controlled Release of Biologically Active Agents*, John Wiley and Sons Inc., NY, p.51, 1987) :

$$M_t/M_\infty = 4 (Dt/\pi l^2)^{0.5} \quad (5)$$

where  $D$  is the coefficient of diffusion,  $l$  is the slab thickness, other symbols representing the same variables as those described above for equation (4). An hydrogel of high water content in which the diffusion of a compound follows the Fick law, is very convenient because the half-life of the release is controlled by the geometry of the hydrogel such as the slab thickness.

- 19 -

Referring now to Figure 5 there is described the theophylline release from hydrogels (active surface: 0.8 to 1.8 cm<sup>2</sup>, thickness 1 mm) prepared with BSA and PEG of various molecular masses. The calculated exponent n and coefficients of diffusion of the related preparations are compiled in Table 3.

**TABLE 3**

Compilation of the values of the exponent n (eq 4) along with the coefficient of correlation of the fit, and the diffusion coefficient (eq.5), assuming a value of  $n = 0.5$ , for the theophylline loaded in pastilles of BSA-PEG prepared with the various molecular masses indicated below. The various pastilles were loaded in triplicate by immersion in solution containing 250 µg/ml of theophylline for 24 hours. The release study was carried out in 30 ml of PBS at room temperature.

PEG	(ratio)	Exponent n	r	D (cm <sup>2</sup> /s)
3350	(3:1)	0.564	0.998	12.6·10 <sup>-7</sup>
4600	(1.6:1)	0.570	0.997	13.4·10 <sup>-7</sup>
8000	(1.4:1)	0.533	0.997	15.4·10 <sup>-7</sup>
10000	(1.3:1)	0.556	0.998	16.1·10 <sup>-7</sup>
20000	(0.6:1)	0.568	0.998	17.1·10 <sup>-7</sup>

It can be concluded that for a wet hydrogel, the release of drug from the hydrogel approaches a Fickian mechanism ( $n = 0.5$ ). Other experiences (results not shown herein) have demonstrated that the release time for a given compound is proportional to the thickness of the pastilles. Also, the coefficient of diffusion, calculated assuming  $n = 0.5$ , was found to increase with the decrease of the molecular masses of PEG.

- 20 -

It is to be understood that the present slow or controlled release composition may also contain excipients, such as binders, disintegrating agents, colours, flavours, preservatives, stabilisers, glidants and lubricants, the use of which will be well known to those skilled in the pharmaceutical art. Any therapeutically effective amount of active ingredient that may be loaded into the hydrogel of the present invention can be employed. Experimental examples of some compounds have been specifically given above. However, with the proviso that they do not substantially alter the crosslinking structure of the hydrogels and that preferably the drugs are water-soluble, further examples of active ingredients that may advantageously be incorporated in the present composition are:

DRUG	pH
Acetazolamide Sodium	9.0-10.0
Alphaprodine HCl	4.0-6.0
Amicaproic Acid	6.0-7.6
Aminosuppurate Sodium	6.7-7.6
Aminophylline	8.6-9.0
Aminotryptiline HCl	4.0-6.0
Amobarbital Sodium	9.6-10.4
Anileridine	2.5-3.0
Amphotericin B	7.2-8.0
Ampicillin	5.0-7.0
Anti coagulant Heparin Solution	5.0-7.0
Arginine HCl	5.0-6.5
Atropine Sulfate	3.0-6.5
Atrial Peptides	
Azathioprine Sodium	9.8-11.0
Benztropine Mesylate	5.0-8.0
Betaine HCl	0.80-1.2
Betamathazone Sodium	8.0
Bethanecol Chloride	5.5-7.5
Biperiden Lactate	4.8-5.8
Bleomycin Sulfate	4.5-6.0
Brompheniramine Maleate	5.8-7.0

SUBSTITUTE SHEET

- 21 -

DRUG	pH	DRUG	pH
Bupivacaine-Epinephrine Injection	3.3-8.5	Daunorubicin HCl	4.5-6.5
Bupivacaine HCl	4.0-6.5	Deslanoside	5.5-7.0
Butabarbital Sodium	10.0-11.2	Desmopressin Acetate	3.0-5.0
Butorphanol Tartrate	3.0-5.5	Dexamethasone Sodium Phosphate	7.0-8.5
Caffeine-Sodium Benzoate Injection	6.5-8.5	Diatrizoate Meglumine	6.0-7.7
Calcium Gluceptate Injection	5.6-7.0	Diatrizoate Sodium	4.5-7.5
Calcium Levulinate	6.0-8.0	Diazepam	6.2-6.9
Carboprost Tromethamine Injection	7.0-8.0	Diazoxide	11.2-11.9
Cefamandole Sodium	6.0-8.5	Dibucaine HCl	4.5-7.0
Cefamandole Nafate	6.0-8.0	Dicyclomine HCl	5.0-5.5
Cephazolin Sodium	4.5-7.0	Diethylstilbesterol Diphosphate	--
Cafatamine Sodium	4.5-6.5	Digoxin	--
Ceftizoxime Sodium	4.5-6.5	Dihydroergotamine Mesylate	3.2-4.0
Cephalothin Sodium	4.5-8.0	Diphenhydramine HCl	4.0-6.5
Caphaprin Sodium	6.5-8.0	Dimenhydrinate	6.4-7.2
Caphradine	8.0-9.6	Dobutamine HCl	2.5-5.5
Cafonocid Sodium	--	Dopamine HCl	2.5-5.5
Chloramphenicol	5.0-8.0	Dopamine HCl Dextrose	3.0-5.0
Chlordiazepoxide HCl	2.5-3.5	Doxapram HCl	3.5-5.0
Chloroprocaine HCl	2.7-4.0	Doxorubicin HCl	3.8-6.5
Chlorothiazide Sodium	9.2-10.0	Droperidol	3.0-3.8
Chlorpromazine HCl	3.0-5.0	Dyphylline	5.0-8.0
Cefoperazone Sodium	4.5-6.5	Edetate Disodium	6.5-7.5
Chlorpheniramine Maleate	4.0-5.2	Emetine HCl	3.0-4.0
Chloroquine HCl	5.5-6.5	Ephedrine Sulfate	4.5-7.0
Chlortetracycline HCl	2.3-3.3	Epinephrine	2.5-5.0
Clorprothixene	4.0-5.0	Ergonovine Maleate	2.7-3.5
Colchicine Desmopressin	6.0-7.0	Ergotamine Tartrate	3.0-4.0
Clindamycin Phosphate	5.5-7.7	Erythromycin	--
Cimetidine Hydrochloride	4.0-6.0	Erythromycin Ethylsuccinate	6.0-8.5
Codeine Phosphate	3.0-6.0	Erythromycin Gluceptate	6.0-8.0
Corticotropin	2.5-6.0	Erythromycin Lactibionate	6.5-7.5
Cyanocobalamin	4.5-7.0	Estradiol Valerate	--
Cyclizine Lactate	3.2-4.7	Ethacrynate Sodium	6.3-7.7
Cyclophosphamide	3.9-6.7	Ethylnorepinephrine HCl	2.5-5.0
Cyclosporine	--	Etidocaine HCl	11.0
Cysteine HCl	1.0-2.5	Fentanyl Citrate	4.0-7.5
Chlorprothixene HCl	3.4	Floxuridine	4.0-5.5
Dantrolene Sodium	9.5	Fluorescein Sodium	8.0-9.0
Dacarbazine	3.0-4.0	Fluoracil	8.6-9.0
Cactinomycin	5.5-7.5	Fluphenazine Enanthate	--

SUBSTITUTE SHEET

- 22 -

DRUGS	pH	DRUGS	pH
Fluphenazine HCl	4.8-5.2	Methlorethamine HCl	3.0-5.0
Folic Acid	8.0-11.0	Memotropine	6.0-7.0
Furosemide	8.5-9.3	Meperidine HCl	3.5-6.0
Fallamine Triethiodide	5.3-7.0	Mephentermine HCl	4.0-6.5
Gentamycin Sulfate	3.0-5.5	Mepivacaine HCl	4.5-6.8
Glucagon	2.5-3.0	Mepivacaine HCl-Levonordefrin	3.3-5.5
Glycopyrrolate	2.0-3.0	Meprylcaine HCl-Epiniphrine	3.5-5.5
Haloperidol	3.0-3.8	Mesoridazine Besylate	4.0-5.0
Heparin-Calcium	5.0-7.5	Metaraminol Bitartrate	3.2-4.5
Heparin-Sodium	5.0-7.5	Methadone HCl	3.0-6.5
Hetacillin-Potassium	7.0-9.0	Methicillin Sodium	5.0-7.5
Hexafluorenum Bromide	4.0-7.0	Methiodal Sodium	5.0-8.0
Histamine Phosphate	3.0-6.0	Methocarbamol	3.5-6.0
Hyaluranidase	6.4-7.4	Methohexital Sodium	10.6-11.6
Digitoxin	--	Methotrexate Sodium	8.0-9.0
Fructose	3.0-6.0	Methotrimeprazine	3.0-5.0
Hydralazine HCl	3.4-4.4	Methoxamine HCl	3.0-53.0
Hydrocortisone Sodium Phosphate	7.5-8.5	Methacopolamine Bromide	4.5-6.0
Hydrocortisone Sodium Succinate	7.0-8.0	Methyldopate HCl	3.0-4.2
Hydromorphone HCl	4.0-5.0	Methylergonovine Maleate	2.7-3.5
Hydroxocobalamin	3.5-5.0	Methylpredisolone Sodium Succinate	7.0-8.0
Hydroxyzine HCl	3.5-6.0	Metronidazole	4.5-7.0
Hyoscyamine Sulfate	3.0-4.5	Miconazole	3.7-5.7
Imipramine HCl	4.0-5.0	Minocycline HCl	2.0-3.5
Iophendylate	6.5-7.7	Mitomycin	6.0-8.0
Iothalamate Sodium	6.5-7.7	Morphine Sulfate	2.5-6.0
Iron Dextran	5.2-6.5	Moxalactam Disodium	4.5-7.0
Isobucaine HCl-Epinephrine	--	Nafcillin Sodium	6.0-8.5
Isoniazid	6.0-7.0	Naloxone HCl	3.0-4.5
Isoproterenol HCl	3.5-4.5	Neostigmine Methylsulfate	5.-6.5
Isoxsuprine HCl	4.9-6.0	Netilmicin Sulfate	3.5-6.0
Kanamycin Sulfate	3.5-5.0	Niacin	4.0-6.0
Ketamine HCl	3.5-4.5	Niacinimide	5.0-7.0
Leucovorin Calcium	6.5-8.5	Norepinephrine Bitartrate	3.0-4.5
Levallorphan Tartrate	4.0-4.5	Nylidrin HCl	4.5-6.5
Lidocaine HCl	5.0-7.0	Orphenadrine Citrate	5.0-6.0
Lidocaine HCl Dextrose	3.5-7.0	Oxacillin Sodium	5.0-8.5
Lidocaine HCl-Epinephrine	3.3-5.5	Oxymorphone HCl	2.7-4.5
Lidocaine HCl-Epinephrine-Bitartrate	3.3-5.5	Oxytetracycline	8.0-9.0
Lincomycin HCl	3.0-6.6	Oxytetracycline HCl	2.0-3.0
Magnesium Sulfate	5.5-7.0	Oxytocin	2.5-4.5
Magnesium Chloride	1.5-2.5	Papaverine HCl	3.0 or less
		Parathyroid	2.5-3.5

SUBSTITUTE SHEET



DRUGS	pH	DRUGS	pH
Penicillin G Potassium	6.5-8.5	Sisomycin Sulfate	2.5-5.5
Penicillin G Procaine	5.0-7.5	Spectinomycin HCl	3.8-5.6
Penicillin G Sodium	6.5-7.5	Streptomycin Sulfate	5.0-8.0
Pentazocine Lactate	4.0-5.0	Succinylcholine Chloride	3.0-4.5
Phenobarbital Sodium	9.0-10.5	Sulfadiazine Sodium	8.5-10.5
Perphenazine	4.2-5.6	Sulfixoxazole Diolamine	7.0-8.5
Phenobarbital Sodium	9.2-10.2	Superoxide Dismutase	--
Phentolamine Mesylate	4.5-6.5	Terbutaline Sulfate	3.0-5.0
Phenylephrine HCl	3.0-6.5	Testosterone Cypionate	--
Phenytoin Sodium	10.0-12.3	Testosterone Enanthate	--
Physostigmine Salicylate	4.0-6.0	Tetracaine HCl	3.2-6.0
Phytonadione	3.5-7.0	Tetracycline HCl	2.0-3.0
Plicamycin	5.0-7.5	Tetracycline Phosphate Complex	2.0-3.0
Posterior Pituitary	2.5-4.5	Thiamine HCl	2.5-4.5
Potassium Acetate	5.5-8.0	Thimylal Sodium	10.7-11.5
Potassium Chloride	4.0-8.0	Thiethylperazine Maleate	3.0-4.0
Prednisolone Sodium Phosphate	7.0-8.0	Thiopental Sodium	10.2-11.2
Prednisolone Sodium Succinate	5.7-8.0	Thiothixene HCl	2.5-3.5
Prilocaine HCl	5.0-7.0	Tobramycin Sulfate	6.0-8.0
Procainamide HCl	4.0-6.0	Tolazoline HCl	3.0-4.0
Procaine HCl	3.0-5.5	Tolbutamide Sodium	8.0-9.0
Procaine HCl-Epinephrine	3.0-5.5	Triamcinolone Diacetate	6.0
Procaine-Phenylephrine	--	Tridihexethyl Chloride	5.0-7.0
Hydrochlorides	3.0-5.5	Trifluoperazine HCl	4.0-5.0
Procaine and Tetracaine HCl	3.5-5.0	Triflupromazine HCl	3.5-5.2
and Levonodofrin		Trimethaphan Camsylate	4.9-5.6
Prochlorperazine Edisylate	4.2-6.2	Trimethobenzamide HCl	4.8-5.2
Promazine HCl	4.0-5.5	Trimethoprim-sulfamethoxazole	10.0
Promethazine HCl	4.0-5.5	Tromethamine	10.0-11.5
Propiomazine HCl	4.7-5.3	Tubocurarine Chloride	2.5-5.0
Propoxycaïne-Procaine HCl's-	3.5-5.0	Vasopressin	2.5-4.5
Norepinephrine Bitartrate		Vincristine Sulfate	3.5-4.5
Propanolol HCl	2.8-4.0	Vidarabine Concentrate	5.0-6.2
Protein Hydrolysate	4.0-7.0	Vinclastine Sulfate	3.5-5.0
Pyridostigmine Bromide	4.5-5.5	Warfarin Sodium	7.2-8.3
Pyridoxine HCl	2.0-3.8	Verapamil	4.1-6.0
Quinidine Gluconate	--		
Reserpine	3.0-4.0		
Riboflavin	4.5-7.0		
Ritodrine HCl	4.8-5.5		
Rolitetracycline	3.0-4.5		
Scopolamine	3.5-6.5		
Secobarbital Sodium	9.0-10.5		

Examples of standard dosage form are reflected in the table below:

DRUGS	DOSAGE
Cimetidine HCl	150 mg/ml
Diazepam	5 mg/ml
5-Fluorouracil	500 mg/ 10 ml
Erythromycin Lactobionate	1 mg/ml
Flosuridine	500 mg/ 5 ml
Amthoteracin D	0.1 mg/ml
Fluphenazine HCl	2.5 mg/ml
Heparin Sodium	1,00-20,000 units/ml
Haloperidol Lactate	5 mg/ml
Insulin	40 units
Ketamine HCl	10 mg/ml
Labeltol HCl	5 mg/ml
Lipocaine HCl	10 mg/ml
Miconazole	10 mg/ml
Morphine Sulfate	0.5-1.0 mg/ml
Dropendal	2.5 mg/ml
Imipramine HCl	25 mg/ 2 ml
Phenytoin	100 mg/ml
Pentobarbital Sodium	50 mg/ml
Tetracycline HCl	250 mg/ 100 ml
Thiopental Sodium	0.2 mg/ 2 ml
Verapamil HCl	2.5 mg/ml
Vincristine Sulfate	1.0 mg/ml
Fentanyl citrate	0.05 mg/ml
Methylprednisolone Sodium Succinate	-- 40 mg/ml

It is to be understood that the above list of drugs is for the purpose of illustration only and is not provided as an all inclusive list of the drugs which may be beneficially incorporated in the slow or controlled release composition of the present invention.

#### Matrix for enzyme immobilisation.

In a first step, the albumin type protein was replaced by an enzyme to obtain an enzymic hydrogel. Catalase was the first enzyme tested. Following the method set forth above, a gel was obtained but it rapidly redissolved during the washing steps. It is thought that this can be explained by the fact that catalase is composed of 4 subunits which were probably dissociated by the swelling force during the water uptake by the hydrogel. This example clearly demonstrates the unexpected important role of albumin protein in maintaining the integrity of the hydrogel structure. Consequently, albumin plays a key role as a co-protein of reticulation, avoiding the redissolution of the hydrogel. It was therefore found that an enzymatic gel would advantageously be prepared with both the enzyme and albumin protein in accordance with the method set forth above.

#### EXPERIMENTAL

100 mg of PEG dinitrophenyl carbonate of Mr 10,000 were mixed with 40 mg of BSA and 10 mg of acid phosphatase, catalase, peroxidase, lactase or glucose oxidase in 1.0 ml of borate buffer 0.1 M pH 9.0 and allowed to polymerize in a test tube for 2 hours. The enzymatic hydrogels were then washed in accordance with

the method set forth above and balanced in a buffer adequate for maintaining the enzyme activity. The different enzymatic hydrogels were pushed through a 700  $\mu$ m mesh sieve and their respective activities were qualitatively evaluated in the presence of their respective substrates. The immobilization procedure was successful for all the enzymes immobilized in the PEG-albumin hydrogel. After 7 months of storage at 4°C in a buffer solution, all the enzymatic hydrogels had maintained their bead form and showed residual enzymatic activity.

A more detailed study on the use of these hydrogels as immobilization matrices for enzymes was conducted using acid phosphatase enzyme (potato source). 10 mg of the enzyme were mixed with 40 mg of BSA and 100 mg of PEG, Mr 10,000, in 1.0 ml of borate buffer, pH 8.8. After two hours of polymerization, the enzymatic hydrogel was processed as mentioned before and was balanced with a citrate buffer 50 mM, pH 5.7. When comparing with the soluble enzyme, the apparent  $K_m$  of the immobilized acid phosphatase was slightly higher than the  $K_m$  of the native enzyme using p-nitrophenyl phosphate as substrate and was proportional to the size of the beads as described in Table 4 below.

TABLE 4

Evaluation of the influence of the particle size on the apparent  $K_m$  and the maximum velocity of the phosphatase acid immobilized in the BSA-PEG hydrogel. P-nitrophenylphosphate was used as the substrate.

Kinetic parameters	soluble enzyme	Particles size		
		210 $\mu m$	300 $\mu m$	700 $\mu m$
$K_m$ (mM)	0.42	0.71	0.94	1.49
$V_{max}$ ( $\mu m \text{ min}^{-1} \text{ mg}^{-1}$ )	--	11.2	13.2	9.0

The reaction was carried out in column containing a weighted amounts of immobilized acid phosphatase at room temperature. The flow rate of the p-nitrophenylphosphate (50 mM citrate pH 5.7 containing 0.02% of  $\text{NaN}_3\text{O}$ ) in the column was 0.3 ml/min.

Also, apparent  $K_m$  determined for beads of 300  $\mu m$  prepared with PEG of molecular masses of 4,600, 8,000, 10,000 and 20,000 were found to be 2.32, 1.6, 1.83, 1.09 mM p-nitrophenylphosphate, respectively. The decrease in the apparent  $K_m$  along with the increase of molecular masses of PEG should be explained by an increase of the porosity. As the result of the increase of the porosity, the diffusion constraints applied on the substrate and product in the hydrogel were found to decrease. Data concerning the yield of immobilisation and other characteristics of the enzymatic hydrogel for the acid phosphatase are given in Table 5 below.

TABLE 5

Characteristics of enzymatic hydrogels obtained from a mixture containing 100 mg/ml PEG ( $M_r = 10,000$ ), 20 to 45 mg/ml BSA and 30 to 5 mg/ml of phosphatase acid in 0.1M borate buffer, pH 8.8. After the polymerization, hydrogels were crunched and washed with 50 mM of borate buffer pH 8.8 and then equilibrated with 50 mM citrate buffer pH 5.2. The size of the dry particles was sieved over a 300  $\mu$ m net. Activity of the immobilized enzyme particles was carried out after lyophilisation under optimal conditions (p-npp 10 mM, pH 5.7, flow rate 0.5 ml/min).

Parameters				
Amount of PA added (U)	15	30	60	90
Total protein added (mg) <sup>1</sup>	50	50	50	50
Protein released (mg)	1.35	1.50	1.85	3.05
Coupling yield (%)	97.3	97	96.3	93.9
PEG released (mg)	30.3	30.5	35.7	35.5
Immobilized PA (U)	2.33	5.2	8.1	8.5
Specific activity immobilized (mU/mg)	48	107	168	181
Immobilization yield (%)	16	18	14	10

<sup>1</sup> including BSA and PA (2U/mg) for a total amount of 50 mg of proteins.

Referring now to FIG. 6, when the enzymatic hydrogel was conserved at room temperature (20°C) in a column, and used daily for a two to three hours period in optimal activity conditions (i.e. substrate p-nitrophenylphosphate (p-npp) at saturating level (10 mM) in 50 mM citrate buffer pH 5.7 containing sodium azide at 0.02%), the acid phosphatase hydrogel had a half-live of 169 h. This half-life is to be compared to a value of 150 hours obtained when the bioreactor was continuously operated in presence of 2 mM p-npp at 37°C. This data favorably compares with other data obtained with the same

enzyme immobilized in a polyacrylamide matrix [Cantarella et al., *British Polymer J.*, 20(6), 1988].


5 As another example of enzyme immobilization in hydrogels prepared with albumin and PEG 10,000 of Mr, the enzyme asparaginase of E.coli was used. The determination of the apparent  $K_m$  for the substrate asparagine of the immobilized asparaginase in the hydrogel (slab thickness of 3 mm) was 2.4  $\mu M$  of asparagine compared to 2.2  $\mu M$  for the soluble form of the  
10 enzyme. The immobilization did not change the optimal pH of reaction which stayed at pH: 8.0. The operational stability of the immobilized enzyme in presence of a continuous feeding in substrate extend at 37°C over a 20 days period without significant loss of activity.

15 Although the invention has been described above with respect with one specific form, it will be evident to a person skilled in the art that it may be modified and refined in various ways. It is therefore wished to have it understood that the present invention should not  
20 be limited in scope, except by the terms of the following claims.

What is claimed is:

5        1.        A polymerized hydrophillic water-swella-  
hydrogel consisting essentially of a crosslinked mixture  
of an aqueous solution of activated bifunctionalized  
polyethylene oxide and protein albumin.

10       2.        The hydrogel of claim 1 wherein said activated  
bifunctionalized polyethylene oxide consists of a  
polyethylene derivative of the general formula (I):



wherein

15       X represents a functionalized group able to react with an  
amino, an S-H, an OH or a COOH group, and n may range  
from 45 to 800.

20       3.        The hydrogel of claim 1 wherein said  
polyethylene oxide is polyethylene glycol.

4.        The hydrogel of claim 2 wherein said  
polyethylene oxide is polyethylene glycol.

25       5.        The hydrogel of claim 1 wherein said protein  
albumin is selected from the group consisting of bovine  
serum albumin, lactalbumin and ovalbumin.

30       6.        The hydrogel of claim 2 wherein said protein  
albumin is selected from the group consisting of bovine  
serum albumin, lactalbumin and ovalbumin.

35       7.        The hydrogel of claim 3 wherein said protein  
albumin is selected from the group consisting of bovine  
serum albumin, lactalbumin and ovalbumin.



- 31 -

8. The hydrogel of claim 4 wherein said protein albumin is selected from the group consisting of bovine serum albumin, lactalbumin and ovalbumin.

5

9. A polymerized hydrophillic water-swella-  
ble hydrogel consisting essentially of a crosslinked mixture  
of an aqueous solution of activated bifunctionalized  
polyethylene oxide and protein albumin, wherein said  
10 mixture additionally comprises unreactive polymers of  
molecular mass higher than 100,000.

10. The hydrogel of claim 9 wherein said unreactive  
polymers are polyethylene glycol.

15

11. A method of correcting vision in humans  
consisting of the use of a hydrogel as a contact lens  
device, wherein said hydrogel is a polymerized  
hydrophillic water-swella- ble hydrogel consisting  
essentially of a crosslinked mixture of an aqueous  
20 solution of activated bifunctionalized polyethylene oxide  
and protein albumin.

12. An ophthalmic implant consisting of a  
25 polymerized hydrophillic water-swella- ble hydrogel  
consisting essentially of a crosslinked mixture of an  
aqueous solution of activated bifunctionalized  
polyethylene oxide and protein albumin.

13. A method of administering a physiologically  
active compound to a mammal comprising loading the  
swella- ble hydrogel of claim 1 with a solution comprising  
a therapeutically effective amount of said  
physiologically active compound and administering said  
35 loaded hydrogel to said mammal.

14. The method of claim 13 wherein said loaded hydrogel is accompanied by a physiologically acceptable carrier.

5 15. The method of claim 13 wherein said loaded hydrogel consists of a drug release composition in a physiologically acceptable form suitable for oral, rectal, cutaneous patch or sub-cutaneous implant administration.


10 16. The method of claim 13 wherein said loaded hydrogel constitutes a wound dressing or artificial skin.

15 17. A method of using a hydrogel in a bioreactor or biosensor, as a matrix for the immobilization of cells or enzymes wherein said hydrogel is a polymerized hydrophillic water-swellaable hydrogel consisting essentially of a crosslinked mixture of an aqueous solution of activated bifunctionalized polyethylene oxide  
20 and protein albumin.

1/6

**FIGURE 1**


Effect of the molecular masses of PEG on the gelling time of BSA-PEG hydrogel in two different buffer pHs (filled dots, 0.1M borate buffer pH: 8.8



2/6

**FIGURE 2**


Effect of PEG/ $\text{NH}_2$  ratio on the gel formation. The bars represent the minimum and the maximum at which gel formation occurs.



3/6

FIGURE 3


UV/VIS spectra of hydrogels obtained with PEG, Mr 10,000, cross-linked with different sources of albumins. The hydrogels were swollen in PBS buffer containing sodium azide 0.02%.



4/6


**FIGURE 4**

Fractional release of drugs from hydrogels in PBS buffer



**FIGURE 5**


Slow controlled release of theophylline in PBS at room temperature from hydrogels prepared with BSA and PEG of various molecular masses



6/6

**FIGURE 6**

Operational stability of acid phosphatase immobilized in BSA-PEG, Mr 10,000, in presence of 10 mM of p-nitrophenylphosphate (flow rate of 1,25 ml/min).





## INTERNATIONAL SEARCH REPORT

In national Application No  
PCT/CA 94/00650

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C08H1/00 C08J3/075 G02B1/04 A61L15/32

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C08H C08J G02B A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	BIOTECHNOLOGY TECHNIQUES, vol. 8, no.2, 1994 pages 71-76, D'URSO E.A. 'New hydrogel based on polyethylene glycol cross-linked with bovine serum albumin' see the whole document ---	1-17
X	US,A,4 101 380 (RUBINSTEIN MENACHEM ET AL) 18 July 1978 cited in the application see column 3, line 21 - column 7, line 64; claims; examples ---	1-10
A	EP,A,0 194 807 (NIPPON OILS & FATS CO LTD ) 17 September 1986 --- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

9 March 1995

Date of mailing of the international search report

21.03.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Cousins-Van Steen, G

# INTERNATIONAL SEARCH REPORT

Inventor's Application No  
PCT/CA 94/00650

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US,A,4 973 466 (REICH CARY ) 27 November 1990</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 94/00650

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4101380	18-07-78	CH-A- 601388 DE-A- 2625257	14-07-78 30-12-76
EP-A-0194807	17-09-86	JP-C- 1772731 JP-B- 4062295 JP-A- 61205209 JP-C- 1772746 JP-B- 4062296 JP-A- 61282314 AU-B- 576946 AU-A- 5429186 CA-A- 1262092 CN-B- 1022022 US-A- 4839345	14-07-93 05-10-92 11-09-86 14-07-93 05-10-92 12-12-86 08-09-88 11-09-86 03-10-89 08-09-93 13-06-89
US-A-4973466	27-11-90	US-A- 5124155	23-06-92